title: 2'-Deoxy-2'-spirocyclopropylcytidine revisited: a new and selective inhibitor of the hepatitis C virus NS5B polymerase.
authors.affiliation: Tibotec BVBA, A Division of Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium. tjoncker@its.jnj.com
authors.forename: Tim H M
authors.initials: TH
authors.lastname: Jonckers
authors.forename: Tse-I
authors.initials: TI
authors.lastname: Lin
authors.forename: Christophe
authors.initials: C
authors.lastname: Buyck
authors.forename: Sophie
authors.initials: S
authors.lastname: Lachau-Durand
authors.forename: Koen
authors.initials: K
authors.lastname: Vandyck
authors.forename: Steven
authors.initials: S
authors.lastname: Van Hoof
authors.forename: Leen A M
authors.initials: LA
authors.lastname: Vandekerckhove
authors.forename: Lili
authors.initials: L
authors.lastname: Hu
authors.forename: Jan Martin
authors.initials: JM
authors.lastname: Berke
authors.forename: Leen
authors.initials: L
authors.lastname: Vijgen
authors.forename: Lieve L A
authors.initials: LL
authors.lastname: Dillen
authors.forename: Maxwell D
authors.initials: MD
authors.lastname: Cummings
authors.forename: Herman
authors.initials: H
authors.lastname: de Kock
authors.forename: Magnus
authors.initials: M
authors.lastname: Nilsson
authors.forename: Christian
authors.initials: C
authors.lastname: Sund
authors.forename: Christina
authors.initials: C
authors.lastname: Rydegård
authors.forename: Bertil
authors.initials: B
authors.lastname: Samuelsson
authors.forename: Asa
authors.initials: A
authors.lastname: Rosenquist
authors.forename: Gregory
authors.initials: G
authors.lastname: Fanning
authors.forename: Kristof
authors.initials: K
authors.lastname: Van Emelen
authors.forename: Kenneth
authors.initials: K
authors.lastname: Simmen
authors.forename: Pierre
authors.initials: P
authors.lastname: Raboisson
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D002460:Cell Line; D003562:Cytidine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D004285:Dogs; D004952:Esters; D016174:Hepacivirus / Q000187:drug effects*; D006801:Humans; D008297:Male; D008958:Models, Molecular; D011355:Prodrugs / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D012324:RNA-Dependent RNA Polymerase / Q000037:antagonists & inhibitors*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013141:Spiro Compounds / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors*; D014779:Virus Replication
chemical_list: C554513:2'-deoxy-2'-spirocyclopropylcytidine; D000998:Antiviral Agents; D004952:Esters; D011355:Prodrugs; D013141:Spiro Compounds; D017361:Viral Nonstructural Proteins; D003562:Cytidine; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase